All In MedTech

FDA Clearance Tracker · K253403

FemVue® Controlled Saline-Air Device (FSA-300)

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Dec 15, 2025

Substantially Equivalent

Time to decision

76 days

Received Sep 30, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K253403
Device name
FemVue® Controlled Saline-Air Device (FSA-300)
Applicant
Femasys, Inc.
Applicant location
Cumming, GA
Received
Sep 30, 2025
Decided
Dec 15, 2025
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 884.4530

Every decision under product code LKF

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LKF. The earliest in FDA's data is K772230, decided Jan 3, 1978.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Femasys, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.